Du är här

2016-02-04

Xvivo Perfusion: Report on operations 2015

Strong sales growth and increased EBITDA

FOURTH QUARTER 2015 (OCT - DEC)

· Net sales in the quarter amounted to SEK 32.7 (25.5) million,
corresponding to an increase of 28 percent. Net sales increased by 17
percent in local currency.

· Operating income before depreciation and amortization (EBITDA)
amounted to SEK 6.9 (3.1) million, corresponding to an EBITDA margin
of 21 percent.

· Net income amounted to SEK 2.8 (0.3) million, resulting in earnings
per share of SEK 0.13 (0.01). The figures are affected by
amortization and depreciation of SEK 3.1 (2.6) million.

· Cash flow from operating activities was SEK 2.9 (-5.4) million.
· Net sales of non-Durable goods* in the quarter amounted to SEK 29.1
(25.5) million, corresponding to an increase of 14 percent in SEK.
Sales of non-Durable goods increased by 5 percent in local currency.

· Products for warm perfusion (STEEN Solution™, the XPS™ and products
related to the use of the XPS™) accounted for 40 (34) percent of
total product sales.

· Three XPS™ was delivered during the quarter. One to the US and two
to Europe, whereof one to the world's second largest lung transplant
clinic in Vienna, Austria.

· The China Food and Drug Administration (CFDA) approved STEEN
Solution™ for marketing and clinical use in China.

THE PERIOD 2015 (JAN - DEC)

· Net sales in the period amounted to SEK 120.2 (84.7) million,
corresponding to an increase of 42 percent. Net sales increased by 25
percent in local currency.

· Operating income before depreciation and amortization (EBITDA)
amounted to SEK 18.8 (11.4) million, corresponding to an EBITDA
margin of 16 percent.

· Net income amounted to SEK 5.1 (5.2) million, resulting in earnings
per share of SEK 0.24 (0.25) after depreciation and amortization of
SEK 11.6 (3.9) million had been charged to the period.

· Cash flow from operating activities was SEK 8.6 (-4.6) million.
· Net sales of non-Durable goods* in the period amounted to SEK 106.0
(83.2) million, corresponding to an increase of 27 percent in SEK.
Sales of non-Durable goods increased by 12 percent in local currency.

· Products for warm perfusion (STEEN Solution™, the XPS™ and products
related to use of the XPS™) accounted for 39 (28) percent of total
product sales.

· The first XPS™ was delivered to Europe. During the year a total of 4
clinics in Europe gained access to the XPS™, including the world's
second largest lung transplant clinic in Vienna, Austria.

· The United States Patent and Trademark Office approved a third
patent in the "Preservation and evaluation solution" family, which
means that STEEN Solution™ and the XPS™ have broader patent
protection in the US.

· A strategic decision was made to apply for listing on Nasdaq
Stockholm's main market during 2016.

· The first liver transplant using STEEN Solution™ was performed in
Toronto, Canada, as part of a clinical phase 1 study.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

· A decision was made to apply for listing on the First North Premier
segment as one step on the way to preparing the company for an
application for listing on NASDAQ Stockholm's main market.

· The company has obtained a CE mark for a patent-protected product,
PrimECC®, which has been developed to prime heart-lung machines
before open heart surgery. The company will expand the clinical
documentation for PrimECC® through more clinical studies in 2016.

· At the time of publication of this report, 23 clinics have access to
the XPS™, including 18 clinics in the US and 4 clinics in Europe.

· After the end of the quarter one XPS™ contract was signed in Europe
CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2
p.m. CET on Thursday, February 4, 2016. Telephone: +44 (0) 1452
555566, enter code 68991296.

February 4, 2016
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO

* Durable goods are sales revenues from the XPS™.

For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com

Magnus Nilsson, CEO, +46 31 788 2150,
magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion's business, please refer to
the company's website, www.xvivoperfusion.com

The information was submitted for publication on February 4, 2016 at
8:30 a.m.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in the USA. The XVIVO share is listed on NASDAQ OMX First North and
has the ticker symbol XVIVO. More information can be found on the
website www.xvivoperfusion.com. The Certified Adviser is Redeye,
www.redeye.se.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
-----------------------------------------------------------
http://news.cision.com/xvivo-perfusion/r/report-on-operations-2015,c9907637
http://mb.cision.com/Main/4567/9907637/472548.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.